tetano
Editor, Senior Moderator
J Immunol Methods
. 2023 Sep 11;113558.
doi: 10.1016/j.jim.2023.113558. Online ahead of print. Obtaining a high titer of polyclonal antibodies from rats to the SARS-CoV-2 nucleocapsid protein and its N- and C-terminal domains for diagnostic test development
Michelle Teixeira de Almeida[SUP] 1 [/SUP], Ana Paula Barbosa[SUP] 1 [/SUP], Camila Gasque Bomfim[SUP] 1 [/SUP], Aline Biazola Visnardi[SUP] 1 [/SUP], Tania Churasacari Vinces[SUP] 1 [/SUP], Alexandre Ceroni[SUP] 2 [/SUP], Edison Luiz Durigon[SUP] 3 [/SUP], Cristiane Rodrigues Guzzo[SUP] 4 [/SUP]
Affiliations
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is an enveloped, plus-stranded RNA virus responsible for the Coronavirus Disease 2019 (COVID-19). Patients infected with COVID-19 may be asymptomatic or have symptoms ranging from mild manifestations to severe cases of the disease that could lead to death. The SARS-CoV-2 genome encodes 4 structural proteins, including the Spike protein (S), the Nucleocapsid protein (N), membrane protein (M) and, the envelope (E). The N protein forms a major component of the ribonucleoprotein complex within the virus particle and play a vital role in its transcription and replication. Nevertheless, the S protein was the most important protein in the development of vaccines against COVID-19. However, the decrease in number of registered immunizations against the disease and the rapid drop in neutralizing antibody titers together with looser preventive measures for virus transmission, favored the rapid appearance of new variants of concerns (VOCs) that primarily show mutations in the S protein. This fact makes the N protein a good candidate for the development of diagnostic tests, due to its stability, amino acid conservation, high immunogenicity, and the smaller likelihood of mutation. With the aim of developing a new diagnostic kit based on the N protein, we evaluated the humoral response in female Wistar rats against this target. Three constructions of the N protein were used to inoculate the animals: the full-length protein (Cfull), the N- (NTD), and the C-terminal (CTD) portion of the protein. The immunizations induced the animal's immune response, with specific polyclonal IgG antibodies against the Cfull protein and its fragments. There were not non-specific bind to the protein used as negative control. Anti-Cfull antibodies demonstrated high efficiency in binding to the NTD protein and the antibodies present in the anti-CTD and anti-NTD sera have recognized the Cfull protein, but they were not able to recognize the NTD and CTD proteins, respectively. Our results indicate an efficient protocol for obtaining high antibody titers against the N recombinant proteins of SARS-CoV-2 and its fragments highlighting the Cfull protein, which can be used in new diagnostic kit development.
Keywords: Antibodies; COVID-19; Conserved protein; Diagnosis; Nucleocapsid.
. 2023 Sep 11;113558.
doi: 10.1016/j.jim.2023.113558. Online ahead of print. Obtaining a high titer of polyclonal antibodies from rats to the SARS-CoV-2 nucleocapsid protein and its N- and C-terminal domains for diagnostic test development
Michelle Teixeira de Almeida[SUP] 1 [/SUP], Ana Paula Barbosa[SUP] 1 [/SUP], Camila Gasque Bomfim[SUP] 1 [/SUP], Aline Biazola Visnardi[SUP] 1 [/SUP], Tania Churasacari Vinces[SUP] 1 [/SUP], Alexandre Ceroni[SUP] 2 [/SUP], Edison Luiz Durigon[SUP] 3 [/SUP], Cristiane Rodrigues Guzzo[SUP] 4 [/SUP]
Affiliations
- PMID: 37704125
- DOI: 10.1016/j.jim.2023.113558
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is an enveloped, plus-stranded RNA virus responsible for the Coronavirus Disease 2019 (COVID-19). Patients infected with COVID-19 may be asymptomatic or have symptoms ranging from mild manifestations to severe cases of the disease that could lead to death. The SARS-CoV-2 genome encodes 4 structural proteins, including the Spike protein (S), the Nucleocapsid protein (N), membrane protein (M) and, the envelope (E). The N protein forms a major component of the ribonucleoprotein complex within the virus particle and play a vital role in its transcription and replication. Nevertheless, the S protein was the most important protein in the development of vaccines against COVID-19. However, the decrease in number of registered immunizations against the disease and the rapid drop in neutralizing antibody titers together with looser preventive measures for virus transmission, favored the rapid appearance of new variants of concerns (VOCs) that primarily show mutations in the S protein. This fact makes the N protein a good candidate for the development of diagnostic tests, due to its stability, amino acid conservation, high immunogenicity, and the smaller likelihood of mutation. With the aim of developing a new diagnostic kit based on the N protein, we evaluated the humoral response in female Wistar rats against this target. Three constructions of the N protein were used to inoculate the animals: the full-length protein (Cfull), the N- (NTD), and the C-terminal (CTD) portion of the protein. The immunizations induced the animal's immune response, with specific polyclonal IgG antibodies against the Cfull protein and its fragments. There were not non-specific bind to the protein used as negative control. Anti-Cfull antibodies demonstrated high efficiency in binding to the NTD protein and the antibodies present in the anti-CTD and anti-NTD sera have recognized the Cfull protein, but they were not able to recognize the NTD and CTD proteins, respectively. Our results indicate an efficient protocol for obtaining high antibody titers against the N recombinant proteins of SARS-CoV-2 and its fragments highlighting the Cfull protein, which can be used in new diagnostic kit development.
Keywords: Antibodies; COVID-19; Conserved protein; Diagnosis; Nucleocapsid.